Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713648 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00713648 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 41 participants.
The verdict
NCT00713648, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The trial is conducted in Europe, North America and Asia. The aim of this trial is to evaluate catridecacog (recombinant factor XIII (rFXIII)) treatment in patients with inherited FXIII deficiency. It is expected that recombinant FXIII can be used for the prevention of bleeding episodes.
Interventions
- DRUG catridecacog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713648
The ClinicalTrials.gov registry entry for NCT00713648 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which catridecacog is the first listed.
NCT00713648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00713648 about?
NCT00713648 is a clinical study titled "Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency". The trial is conducted in Europe, North America and Asia. The aim of this trial is to evaluate catridecacog (recombinant factor XIII (rFXIII)) treatment in patients with inherited FXIII deficiency. It is expected that recombinant FXIII can be used for the prevention of bleeding episodes.
What is the current status of trial NCT00713648?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2008-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00713648?
The interventions under investigation include: catridecacog (DRUG).
Who is sponsoring clinical trial NCT00713648?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.